Company Description
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland.
The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue.
It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors.
Profound Medical Corp. is headquartered in Mississauga, Canada.
| Country | Canada |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 142 |
| CEO | Arun Menawat |
Contact Details
Address: 2400 Skymark Avenue, Unit 6 Mississauga, ON L4W 5K5 Canada | |
| Phone | 647 476 1350 |
| Website | profoundmedical.com |
Stock Details
| Ticker Symbol | PROF |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001628808 |
| CUSIP Number | 74319B502 |
| ISIN Number | CA74319B5027 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Arun Swarup Menawat MBA, Ph.D. | Chairman of the Board and Chief Executive Officer |
| Dr. Mathieu Burtnyk Ph.D. | President |
| Rashed Dewan | Chief Financial Officer |
| Thomas Tamberrino MBA | Chief Commercial Officer |
| Stephen Kilmer | Investor Relations |
| Matthew Sobczyk C.A., CPA | Assistant Corporate Controller |
| Levant Tinaz | Software Developer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 4, 2025 | 8-K | Current Report |
| May 14, 2025 | 8-K | Current Report |
| May 8, 2025 | 8-K | Current Report |
| May 8, 2025 | 10-Q | Quarterly Report |
| Apr 29, 2025 | 8-K | Current Report |
| Apr 29, 2025 | 8-K | Current Report |
| Apr 22, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 6-K/A | Filing |
| Mar 10, 2025 | 6-K/A | Filing |
| Mar 10, 2025 | 6-K/A | Filing |